Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 6'-fluoro-4',9'-dihydro-n,n-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'h)-pyrano(3,4-b)indol)-4-amine
1. 863513-91-1
2. Grt6005
3. Grt-6005
4. Grt 6005
5. 863513-93-3
6. 7gdw9s3gn3
7. Cebranopadol ((1alpha,4alpha)stereoisomer)
8. 863513-91-1 (free Base)
9. (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
10. 6-fluoro-n,n-dimethyl-1'-phenylspiro[4,9-dihydro-3h-pyrano[3,4-b]indole-1,4'-cyclohexane]-1'-amine
11. Spiro(cyclohexane-1,1'(3'h)-pyrano(3,4-b)indol)-4-amine, 6'-fluoro-4',9'-dihydro-n,n-dimethyl-4-phenyl-, Trans-
12. Trans-6'-fluoro-n,n-dimethyl-4-phenyl-4',9''-dihydro-3'h-spiro(cyclohexane-1,1'-pyrano(3,4-b)indol)-4-amine
13. 6-fluoro-n,n-dimethyl-1'-phenyl-spiro[4,9-dihydro-3h-pyrano[3,4-b]indole-1,4'-cyclohexane]-1'-amine
14. Cebranopadol [inn]
15. Cebranopadol [usan:inn]
16. Unii-7gdw9s3gn3
17. Cebranopadol (usan/inn)
18. Cebranopadol [usan]
19. Cebranopadol(grt-6005)
20. Schembl154336
21. Schembl566256
22. Gtpl8866
23. Chembl2364605
24. Chembl3545616
25. Chembl3962932
26. Schembl10035739
27. Schembl14183935
28. Schembl19336241
29. Bdbm177926
30. Dtxsid001031965
31. Bcp09612
32. Ex-a1095
33. Zinc3950145
34. Bdbm50101095
35. Bdbm50101112
36. Bdbm50533342
37. Akos025290738
38. Cs-1323
39. Db12830
40. Sb16531
41. Ncgc00378895-01
42. Ncgc00378895-02
43. Ac-36077
44. As-35183
45. Hy-15536
46. Ft-0774945
47. D10436
48. Us9120797, 24
49. Us9120797, 25
50. Q19596315
51. (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indole]-4-amine
Molecular Weight | 378.5 g/mol |
---|---|
Molecular Formula | C24H27FN2O |
XLogP3 | 4.3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 2 |
Exact Mass | 378.21074165 g/mol |
Monoisotopic Mass | 378.21074165 g/mol |
Topological Polar Surface Area | 28.3 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 553 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of chronic pain
Details:
TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Lead Product(s): Cebranopadol
Therapeutic Area: Neurology Brand Name: TRN-228
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2025
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris’ Cebranopadol Shows Positive Phase 3 Results in Acute Pain
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 06, 2025
Details:
TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Lead Product(s): Cebranopadol
Therapeutic Area: Neurology Brand Name: TRN-228
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 28, 2025
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Reports Low Abusability for Cebranopadol Pain Therapy
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 28, 2025
Details:
TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Lead Product(s): Cebranopadol
Therapeutic Area: Neurology Brand Name: TRN-228
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2025
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Presents Positive ALLEVIATE-1 Trial Data for Cebranopadol in Acute Pain
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 22, 2025
Details:
TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Lead Product(s): Cebranopadol
Therapeutic Area: Neurology Brand Name: TRN-228
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 21, 2024
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Starts ALLEVIATE-1 and 2 Trials of Cebranopadol for Pain Treatment
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 21, 2024
Details:
Funding will support the studies of Cebranopadol, the first and only full, dual NOP/MOP receptor agonist and has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment for OUD.
Lead Product(s): Cebranopadol
Therapeutic Area: Psychiatry/Psychology Brand Name: TRN-228
Study Phase: IND EnablingProduct Type: Controlled Substance
Sponsor: National Institute on Drug Abuse
Deal Size: $16.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 28, 2023
Lead Product(s) : Cebranopadol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : National Institute on Drug Abuse
Deal Size : $16.6 million
Deal Type : Funding
Details : Funding will support the studies of Cebranopadol, the first and only full, dual NOP/MOP receptor agonist and has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment f...
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 28, 2023
Details:
Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain.
Lead Product(s): Cebranopadol
Therapeutic Area: Neurology Brand Name: TRN-228
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 13, 2022
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain.
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 13, 2022
Details:
Park Therapeutics is developing a unique, first-in-class, investigational NCE for the treatment of pain which is Phase III-ready. With the acquisition, Tris owns worldwide rights and all accompanying intellectual property for cebranopadol.
Lead Product(s): Cebranopadol
Therapeutic Area: Neurology Brand Name: PRK-101
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Tris Pharma Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 29, 2021
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Tris Pharma Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Tris Pharma® Announces Acquisition of Park Therapeutics – Pain Company with First-in-class, Pha...
Details : Park Therapeutics is developing a unique, first-in-class, investigational NCE for the treatment of pain which is Phase III-ready. With the acquisition, Tris owns worldwide rights and all accompanying intellectual property for cebranopadol.
Product Name : PRK-101
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 29, 2021
ABOUT THIS PAGE
93
PharmaCompass offers a list of Cebranopadol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cebranopadol manufacturer or Cebranopadol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cebranopadol manufacturer or Cebranopadol supplier.
PharmaCompass also assists you with knowing the Cebranopadol API Price utilized in the formulation of products. Cebranopadol API Price is not always fixed or binding as the Cebranopadol Price is obtained through a variety of data sources. The Cebranopadol Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cebranopadol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cebranopadol, including repackagers and relabelers. The FDA regulates Cebranopadol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cebranopadol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Cebranopadol supplier is an individual or a company that provides Cebranopadol active pharmaceutical ingredient (API) or Cebranopadol finished formulations upon request. The Cebranopadol suppliers may include Cebranopadol API manufacturers, exporters, distributors and traders.
Cebranopadol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cebranopadol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cebranopadol GMP manufacturer or Cebranopadol GMP API supplier for your needs.
A Cebranopadol CoA (Certificate of Analysis) is a formal document that attests to Cebranopadol's compliance with Cebranopadol specifications and serves as a tool for batch-level quality control.
Cebranopadol CoA mostly includes findings from lab analyses of a specific batch. For each Cebranopadol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cebranopadol may be tested according to a variety of international standards, such as European Pharmacopoeia (Cebranopadol EP), Cebranopadol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cebranopadol USP).